Vincristine (NSC-67574) sulfate

For research use only. Not for use in humans.

目录号：S1241 别名： Leurocristine, Oncovin, 22-Oxovincaleukoblastine 中文名称：硫酸长春新碱

Vincristine (NSC-67574) sulfate Chemical Structure

CAS No. 2068-78-2

Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine)通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。Vincristine sulfate可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 734.41	现货
10mg	RMB 582.05	现货
50mg	RMB 2229.59	现货
200mg	RMB 7118.45	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vincristine (NSC-67574) sulfate发表文献97篇：

Nat Cell Biol, 2022, 10.1038/s41556-021-00814-7

PubMed: 35145224 ( click the link to review the publication )

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Mol Cell, 2022, 82(1):75-89.e9

PubMed: 34942120 ( click the link to review the publication )

Dis Model Mech, 2022, dmm.049109

PubMed: 35199829 ( click the link to review the publication )

Toxicology, 2022, 471:153175

PubMed: 35395335 ( click the link to review the publication )

Hum Cell, 2022, 10.1007/s13577-022-00671-y

PubMed: 35118583 ( click the link to review the publication )

Theranostics, 2021, 11(9):4281-4297

PubMed: 33754061 ( click the link to review the publication )

Cell Rep, 2021, 36(11):109718

PubMed: 34525361 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109302

PubMed: 34192534 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):97

PubMed: 34315482 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):789

PubMed: 34385422 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-0864

PubMed: 33850006 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13145

PubMed: 34850536 ( click the link to review the publication )

J Neurochem, 2021, 156(5):642-657

PubMed: 32654140 ( click the link to review the publication )

Chemosphere, 2021, S0045-6535(21)03256-2

PubMed: 34742755 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Chem Biol Interact, 2021, 340:109448

PubMed: 33775687 ( click the link to review the publication )

Toxicol Lett, 2021, 340:67-76

PubMed: 33429010 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2021, gmab101

PubMed: 34363072 ( click the link to review the publication )

Hum Cell, 2021, 34(6):1911-1918

PubMed: 34383271 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00639-4

PubMed: 34731453 ( click the link to review the publication )
Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-1315

PubMed: 32826328 ( click the link to review the publication )

Oncogene, 2020, 39(17):3555-3570

PubMed: 32123312 ( click the link to review the publication )

Environ Sci Technol, 2020, 54(23):15267-15276

PubMed: 33201683 ( click the link to review the publication )

Cancer Lett, 2020, 469:111-123

PubMed: 31639426 ( click the link to review the publication )

J Pathol, 2020, 10.1002/path.5591

PubMed: 33206391 ( click the link to review the publication )

BMC Biol, 2020, 22;18(1):42

PubMed: 32321486 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02933-w

PubMed: 33057863 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 17;14(4):e0008224

PubMed: 32302296 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicology, 2020, 429:152329

PubMed: 31733235 ( click the link to review the publication )

Vet Comp Oncol, 2020, 10.1111/vco.12656

PubMed: 33025640 ( click the link to review the publication )

Biol Open, 2020, bio.050211

PubMed: 33372065 ( click the link to review the publication )

Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Med Rep, 2020, 22(4):2791-2800

PubMed: 32945456 ( click the link to review the publication )

Neuroreport, 2020, 31(3):197-204

PubMed: 31834144 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )
Int J Med Sci, 2020, 17(11):1652-1664

PubMed: 32669967 ( click the link to review the publication )

Cancer Res, 2019, 79(20):5382-5393

PubMed: 31405846 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 31742555 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6175

PubMed: 31817853 ( click the link to review the publication )

J Cell Biochem, 2019, 120(10):17791-17810

PubMed: 31264739 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Exp Med, 2018, 215(8):2137-2155

PubMed: 30045945 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1070

PubMed: 30341283 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3094-3114

PubMed: 30404791 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )
Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(10):2506-2515

PubMed: 27780854 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(8):1555-1565

PubMed: 28522589 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(24):39064-39076

PubMed: 28388564 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Int J Anal Chem, 2015, 2015:743915

PubMed: 27034675 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )
Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述

Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine)通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。Vincristine sulfate可诱导凋亡。

靶点

Microtubules ^[1]
(Cell-free assay)

32 μM

体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用，K_i为85 nM。^[1]在低浓度时，Vincristine抑制纺锤体，使染色体分离失败，进而导致中期停滞，并抑制有丝分裂。在较高浓度时，Vincristine可能干扰且诱导全部微管解聚。^[2] Vincristine 诱导肿瘤细胞凋亡，且抑制SH-SY5Y细胞增殖，IC50为0.1 µM。Vincristine诱导有丝分裂停滞，促进caspase-3和-9及cyclin B的表达，但降低cyclin D的表达。^[3] Vincristine通过干扰微管功能而诱导神经毒性形成，这会导致轴突运输堵塞，从而导致轴突变性。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	NH3uWXlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MlvsNE0xNjVizszN	M3XKRlI1KGh?		NXHQeG17\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	NEfnTYxCeG:ydH;zbZMhSXO\|YYm=	MmfjNE0xNjVizszN	MUWyOEBp		M{XY[Ylv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	NUXPeYdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2.2.15	NWHNPIdZTnWwY4Tpc44hSXO\|YYm=	M3nydFAvOSEQvF2=	MnvSNlQhcA>?		NHfxZYxxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44>	NVTae\|lTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	NV3aWHRVTnWwY4Tpc44hSXO\|YYm=	NYHFb4Y3OC5zIN88US=>	M4LSdFI1KGh?		Mnj6dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	M3rZTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	NYTtRVdkTnWwY4Tpc44hSXO\|YYm=	M2DGOlAvOSEQvF2=	MUK0PEBp		MorKdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW\|IFThcoUheGG{dHnjcIV{	NFewSVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2N\|c3QSd-MkW2OlM4Pjl:L3G+
HepG2-HBV1.1	NVTVOoZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTOS\|cxNjFizszN	M4iwblEuPSCm		MmnwbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?=	NFPCPVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2N\|c3QSd-MkW2OlM4Pjl:L3G+
HepG2-HBV1.1	NHLyUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjpTlFXOC5zIN88US=>	MVixMVUh\A>?		NVLhbHpEcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	M1n4blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjtcZY2OC5zIN88US=>	MUWxNk04OiCq		NUHvcVlwcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	NHPJdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHaPY9mOC5zIN88US=>	M1jUUlEzNTd{IHi=		M2HH[olv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=>	MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NkO3OlkoRjJ3Nk[zO\|Y6RC:jPh?=
Raji	NHPPdXdHfW6ldHnvckBCe3OjeR?=	MV2wMlXDqM7:TR?=	MlvzO\|IhcA>?		NXrtWoxn[WKxbHnzbIV{KGG3dH;wbIFogcLi	M3\q[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES2N\|c4Lz5{NUS0OlM4PzxxYU6=
SK-MEL-28	NUn0UXpDTnWwY4Tpc44hSXO\|YYm=	NIPqfZE{OCCwTR?=	NUjISWVoPiCq		M4XxeIlv\HWlZYOgS\|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2	NY\4VlZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNVMxOTBpPkK1N\|E{ODFyPD;hQi=>
H157	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILFTJRKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?=	MlrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe5NVEoRjJ3MkW3PVEyRC:jPh?=
Jurkat	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW2PGNROS1\|IH7N	M3HpNVQ5yqCq	MUXEUXNQ	NETVNFFl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6	NWi1UHpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVYyPDZpPkK1NVU3OTR4PD;hQi=>
CEM	Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkKzNU0{KG6P	Mli0OFjDqGh?	MWfEUXNQ	MmPK[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3NkG0Okc,OjVzNU[xOFY9N2F-
P12	NU\5N5FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHxNU0{KG6P	M2jJSVQ5yqCq	MkW0SG1UVw>?	MUDk[YNz\WG\|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5	M17qdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUW2NVQ3Lz5{NUG1OlE1PjxxYU6=
KB	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vSZ2lEPTB;MD6wNFQ6KMLzIECuNFAxOSEQvF2=	Mnj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUi1NlYoRjJ3MEW4OVI3RC:jPh?=
KBv200 (ABCB1)	NGTOV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjHTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?=	MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUi1NlYoRjJ3MEW4OVI3RC:jPh?=
SUDHL6	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDudI4y6oDLzszN	MXe0PE84OiCq		M{PMbIlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	MmHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkG2NFQoRjJ2OU[xOlA1RC:jPh?=
SUDHL6	M3LOOWZ2dmO2aX;uJGF{e2G7	M3[wTVHjiIoQvF2=	NUe4SpcxPzJiaB?=		MV;pcoR2[2W\|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C	NUHBSXdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE3ODRpPkK0PVYyPjB2PD;hQi=>
HCT-116	NGH3RVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13MSmdKPTB;NTDuUS=>	NH3MeGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyO\|g2Pyd-MkS5Nlc5PTd:L3G+
SKNBe2C	NVHW[nh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTN{LklCtVQvOCCwTR?=	NIrESmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyNVkzOCd-MkS5NlE6OjB:L3G+
IGNR91	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJ2LkRCtVEvPyCwTR?=	Ml7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
SKNAS	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPheHM2UUN3ME2xMlXDuTBwMjDuUS=>	M1TPelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKxPVIxLz5{NEmyNVkzODxxYU6=
LAN1	NHzJN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTJT3pGUUN3ME2yMlPDuTBwMjDuUS=>	NUXRPI1yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlE6OjBpPkK0PVIyQTJyPD;hQi=>
SHSY5Y	NFXzSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXVSZhHUUN3ME24MlLDuTBwNjDuUS=>	NYn0O25ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlE6OjBpPkK0PVIyQTJyPD;hQi=>
A549-WT	M{LFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{WwT2lEPTB;MUmuOFM4KMLzIECuOVk1KCCwTR?=	NXThbXE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
A549-R	NGLyVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTBTZJXUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N	NXy1S5VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-WT	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrKTWM2OD1zNz63OVIhyrFiMD6yNVghKG6P	NWTwOVhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-R	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHj[W5EUUN3ME21MlU{QSEEsTCwMlE1PCBibl2=	Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUi4NlcoRjJ2OEW4PFI4RC:jPh?=
A549-R	MYHDfZRwfG:6aXPpeJkhSXO\|YYm=				NFvQe\|lKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?=	Ml33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUi4NlcoRjJ2OEW4PFI4RC:jPh?=
MCF-7-R	MoGyR5l1d3SxeHnjbZR6KEG\|c3H5				NHTyXJlKSzVyPUWuOVM6KMLzIECuNVQ1KG6P	M3eyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW4PFI4Lz5{NEi1PFgzPzxxYU6=
SW620	NX3uXJF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmiwTWM2OD15LkiwJOKyKDBwMEigcm0>	Mnf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[3N\|koRjJ2N{K2O\|M6RC:jPh?=
SW620/AD300	NIPuT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTlyOT62NEDDuSB6LkmxJI5O	NUjzfZhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY4OzlpPkK0O\|I3PzN7PD;hQi=>
HEK293/pcDNA3.1	M17rfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTFwNEWgxtEhOC5{MDDuUS=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkezPUc,OjR5Mk[3N\|k9N2F-
HEK293/ABCC1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTF7LkK5JOKyKDJwMEigcm0>	NUDDO\|ljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY4OzlpPkK0O\|I3PzN7PD;hQi=>
TCC	M{[5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWXGNXB3OjRiaB?=		MoO2TWM2OD15MDDuUS=>	MmqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MU[5OFQoRjJ2N{G2PVQ1RC:jPh?=
TCC	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXq0PEBp		M3LL[WlEPTB;NUCgcm0>	NUi0So1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NVY6PDRpPkK0O\|E3QTR2PD;hQi=>
HepG2/ADM	NXrwc5FVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGK0Z4VKSzVyPUKuO\|g3O8LzMD6yN\|cyKM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDdyNEW1Okc,OjR5MES1OVY9N2F-
HepG2	NUmyd5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwMEGxOeKyOC5yMEG3JO69VQ>?	NGDQXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
MCF-7/ADR	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojjTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1?	M37Mc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
MCF-7	NVT5fHdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTBwMEG1PeKyOC5yME[yJO69VQ>?	M33mWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
A-172	NYHxOm04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW1cXV{OC5zwrFOwG0>	NYPYfWxrOjRxN{KgbC=>		MnO0bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MEKzOUc,OjR3M{CyN\|U9N2F-
U-251MG	NYTqV\|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:wMlHDqM7:TR?=	NGO1NG4zPC95MjDo		M3PQN4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk>	NEDTS2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFI{PSd-MkS1N\|AzOzV:L3G+
DLD-1	M4H6e2Z2dmO2aX;uJGF{e2G7	M{jDdlExOCCwTR?=	NEfYPZQ1QCCq		Ml[wdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	NULSXGdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFM1PTNpPkK0OFA{PDV\|PD;hQi=>
CCD18Co	MmS1SpVv[3Srb36gRZN{[Xl?	MlT4NVAxKG6P	NWDDd\|NLPDhiaB?=		NEXseJFxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB?	NFPvSHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwN\|Q2Oyd-MkS0NFM1PTN:L3G+
DLD-1	NVyxRnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKwMVExODBibl2=	NW\GXlljPDhiaB?=		MWTpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NHnqN449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwN\|Q2Oyd-MkS0NFM1PTN:L3G+
CCD18Co	NYLuZlBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLHNE0yODByIH7N	NEfje2c1QCCq		Mnz6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M2nM[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NECzOFU{Lz5{NESwN\|Q2OzxxYU6=
HepG2	M3:3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1LPOFI1KGh?		NXrrO5VvUUN3ME21Nk426oDLzszN	M4XFd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{SxOlg5Lz5{NEO0NVY5QDxxYU6=
HEK293/pcDNA3.1	M4njcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzzTnBLUUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NEe4N{c,OjR{OES3PFM9N2F-
HEK293/MRP1	M3;4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTBwMEW1xtExNjBzMkCg{txO	M2LIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki0O\|g{Lz5{NEK4OFc5OzxxYU6=
Ramos	NUTRdVYxSXCxcITvd4l{KEG\|c3H5	M172cFLjiIoQvF2=	NFLHXZk1QCCq		MmrRbY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{	Mn60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NU[0PVEoRjJ2MkW2OFkyRC:jPh?=
NCI-H1299/pcDNA3	MkjUR4VtdCCYaXHibYxqfHliQYPzZZk>	NUGzUm5wOC1{MDDuUS=>	NVjIXVJXQTZiaB?=		MnHlbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	M4DQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe3NFEzLz5{NEG3O\|AyOjxxYU6=
H1299/ICAM-3	Mlm3R4VtdCCYaXHibYxqfHliQYPzZZk>	MWSwMVIxKG6P	NEPUUYs6PiCq		MYTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	Mm\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{ewNVIoRjJ2MUe3NFEzRC:jPh?=
NCI-H1299/pcDNA3	NGjFT5BHfW6ldHnvckBCe3OjeR?=	MnK3NU82NzFyL{KwxsBvVQ>?	MkDMPVYhcA>?		M1;3SYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5N{CxNkc,OjRzN{ewNVI9N2F-
H1299/ICAM-3	M2LGeWZ2dmO2aX;uJGF{e2G7	Mn:3NU82NzFyL{KwxsBvVQ>?	NVHnc\|lkQTZiaB?=		M3vTbolv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA>	M1PhT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe3NFEzLz5{NEG3O\|AyOjxxYU6=
W1	NY\lWopiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{mzSWlEPTB;MD6wNFMzKM7:TR?=	NYG4TGx4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
W1VR	NUm4dZZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHriR3hKSzVyPUCuNFU3KM7:TR?=	M1fQPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUSwNVc3Lz5{NEG0NFE4PjxxYU6=
K562	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTBwMEOyJOKyKDBwMECxJEDPxE1?	NX:1[5VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|U6OzdpPkK0NVM2QTN5PD;hQi=>
K562/ADR	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH70UYhKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?=	NILHZpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOVk{Pyd-MkSxN\|U6Ozd:L3G+
K562	NHm2T5ZCeG:ydH;zbZMhSXO\|YYm=	M{S1[FAvOyEQvF2=	M{jobVI1KGh?		NHPmWIpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M2LPNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO1PVM4Lz5{NEGzOVk{PzxxYU6=
K562/ADR	NFzNfZlCeG:ydH;zbZMhSXO\|YYm=	MUizJO69VQ>?	MofINlQhcA>?		MWrpcoR2[2W\|IHHwc5B1d3Orcx?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NUmzO{c,OjRzM{W5N\|c9N2F-
A549	NYTP[VU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTnTIpCUUN3ME2wMlExKMLzIECuNFMh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5MUC3OUc,OjN7N{GwO\|U9N2F-
K562	MnS4R4VtdCCYaXHibYxqfHliQYPzZZk>	MUOzMlc26oDVNkFCpI5O	MlHpO\|LDqGkEoB?=		M{LEe4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MnvJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{eyNlMoRjJ\|OEe3NlI{RC:jPh?=
lucena	NWPKZ3d7S2WubDDWbYFjcWyrdImgRZN{[Xl?	MlPXN{44PeLCk{[wxsBvVQ>?	MVq3NuKhcMLi		MXfuc{Bm\m[nY4S=	M{H4blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NlI{Lz5{M{i3O\|IzOzxxYU6=
FEPS	NI\WWJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NGfTfoM{Njd34pETOlDDqG6P	MWC3NuKhcMLi		NWDjNXRMdm9iZX\m[YN1	M16yN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NlI{Lz5{M{i3O\|IzOzxxYU6=
A2780	NVztVmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXPc2JKSzVyPUOuOUBuVQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUKwN{c,OjN6MkmyNFM9N2F-
ACHN	NE\W[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRDBwMTDtUS=>	NX\GeIFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NlkzODNpPkKzPFI6OjB\|PD;hQi=>
U-937	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvabFBKSzVyPEO0JI5O	NYnBOmNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NlkzODNpPkKzPFI6OjB\|PD;hQi=>
Jurkat	NH;lTWtCeG:ydH;zbZMhSXO\|YYm=	MVG1xsDPxGdxbX\|CpC=>	MUWyOEBp		M{HzVIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUC0NFkoRjJ\|OEGwOFA6RC:jPh?=
Jurkat	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTNVIdTPcLizsznM41tyqB?	M3fiVlI1KGh?		M131ToFzemW\|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG\|ZR?=	NUniNXd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVA1ODlpPkKzPFExPDB7PD;hQi=>
Hep-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLvbppKSzVyPUCuNFTDuTBwMEGg{txO	M3LCeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{iwOFI1Lz5{M{e4NFQzPDxxYU6=
Hep-2/v	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFwONMxNE4zOCEQvF2=	NFvmS2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4NFQzPCd-MkO3PFA1OjR:L3G+
SGC-7901	M3SwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGwMVExKM7:Zz;tcC=>	NVS1eog6OjRxNEivO\|IhcA>?		MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	M3zNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SzOVczLz5{M{e0N\|U4OjxxYU6=
SGC-7901/VCR	M3\EV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jRcVAuOTBizsznM41t	NV7IWJc6OjRxNEivO\|IhcA>?		NVfDXpU1cW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NGriNJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N\|U4Oid-MkO3OFM2PzJ:L3G+
SGC-7901	NH6wPGZCeG:ydH;zbZMhSXO\|YYm=				NUnqZo9icW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	Mm\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEO1O\|IoRjJ\|N{SzOVczRC:jPh?=
SGC-7901/VCR	NEjGOllCeG:ydH;zbZMhSXO\|YYm=				MmWybY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2M{W3Nkc,OjN5NEO1O\|I9N2F-
KB-3-1	M{G1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwNk[gxtEhOC5zNkKg{txO	MnH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-C2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXITWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?=	NVfCNplXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
KB-3-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF:zcWtKSzVyPUGuNlYhyrFiMD6wNlch\|ryP	Mm\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-V1	M2jRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrLXoQ3UUN3ME2yNFgvQDViwsGgNlAvPCEQvF2=	M37BTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkezOFQ2Lz5{M{[3N\|Q1PTxxYU6=
HEK293/pcDNA3.1	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\nS3hKSzVyPUK0MlEhyrFiMD6yNFQh\|ryP	NF\nVlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3N\|Q1PSd-MkO2O\|M1PDV:L3G+
HEK293/ABCB1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVi4RZVDUUN3ME2zOVEzNjhiwsGgN\|c5NjN7MTFOwG0>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5M{S0OUc,OjN4N{O0OFU9N2F-
A549/EGFP	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LHc\|AvODFvMUCwNEDPxE1?			NIKwSmZKSzVyPUi2MlchyrFiMkmuNUDPxE1?	NEnYPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[zOFI5Oid-MkO2N\|QzQDJ:L3G+
A549/Slug	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnPNE4xOS1zMECwJO69VQ>?			NUj2PHU6UUN3ME25MlchyrFiMz6xJO69VQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ\|NEK4Nkc,OjN4M{SyPFI9N2F-
JFCR39	NFXMR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfqWpZbOSEEtV2=	MnKzNlQhcA>?	NGjneG5FVVOR	MkPHcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG\|ZTDj[Yxtew>?	MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUiyO\|YoRjJ\|NUm4Nlc3RC:jPh?=
A549	NUX0bWo3TnWwY4Tpc44hSXO\|YYm=	MknsNVAxKG6P	NU\5d4hROTZiaB?=	NGW1XVNFVVOR	NHv1W\|Zt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW\|	NGX4d489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5PFI4Pid-MkO1PVgzPzZ:L3G+
SGC7901	NFH5TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;ZXIVKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t	M1TuUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/LV-NC	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\STWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=>	MoTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/LV-SGO1	NHvqdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{ewVWlEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NES4Nkc,OjN3NkS0PFI9N2F-
SGC7901/VCR	M2fk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LJ[GlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t	NIOzUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OFQ5Oid-MkO1OlQ1QDJ:L3G+
SGC7901/VCR-NC	NHradHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=>	NV3NT\|ZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/VCR-si-SGO1	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjjXVRKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t	NUDVVpFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR	NEf1XpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S5SGlEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw>	NVHJcXlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR-NC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle2TWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NES4Nkc,OjN3NkS0PFI9N2F-
SGC7901/ADR-si-SGO1	NXq0bJBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\jUmlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw>	MmniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SH-SY5Y	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU[wMlAxOS1zMDFOwG0>	MnvYNlQhcA>?		MmLFTWM2OD1yLkGxN:KyOC5yMUKg{txO	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF{OUC2OUc,OjNzMkmwOlU9N2F-
SH-SY5Y	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoP3NE4xODFvMUCg{txO	MmX5OFghcA>?		NUS3PIZ4UUN3ME2wMlA4QMLzMD6wNFkh\|ryP	NUTBTWxYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	NY\pfpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm3bpBEOC5yMEGtNVAh\|ryP	NWPsbpJFPzJiaB?=		MWjJR\|UxRTBwMEWxxtExNjByODFOwG0>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF{OUC2OUc,OjNzMkmwOlU9N2F-
SH-SY5Y	NXz4Z4hwSXCxcITvd4l{KEG\|c3H5	NWPiOlE6OC5zIN88US=>	NGP6NVAxNTJ2IHi=		MUjpcoR2[2W\|IHHwc5B1d3OrczDv[kBUUC2VWUXZJINmdGy\|IH\vcIxwf2mwZzDj[YxtKGO7Y3zlJIFzemW\|dDDheEB1cGViR{KvUUBxcGG\|ZR?=	NYXt[lhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	NWTP[FUySXCxcITvd4l{KEG\|c3H5	MVWwMlEh\|ryP	MYKwMVI1KGh?		MUTpcoR2[2W\|IH3peI91cWNiYYLy[ZN1yqB?	NH:1[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GyPVA3PSd-MkOxNlkxPjV:L3G+
LNCAP	NHni[3REgXSxdH;4bYNqfHliYYPzZZk>		NYe2eGo2PzJiaILz		Mn7WR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xODJ7IN88UU4>	MnL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB5M{K4NFkoRjJyN{OyPFA6RC:jPh?=
LNCAP	M{nwZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{LUTlczKGi{cx?=		NFLKOZZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjByNkGg{txONg>?	NXLrPHVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU{PDhpPkKzNlE2OzR6PD;hQi=>
PC3	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		MlfSO\|IhcHK\|		NVez[mt7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODFzIN88UU4>	NXnRSFJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3N\|I5ODlpPkKwO\|MzQDB7PD;hQi=>
PC3	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		M{XGVlczKGi{cx?=		MmLQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFE2KM7:TT6=	NWPXT3MxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU{PDhpPkKzNlE2OzR6PD;hQi=>
PC3	Mo\sR5l1d3SxeHnjbZR6KGG\|c3H5		NELreGU4OiCqcoO=		Mln5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMUWzJO69VS5?	M3fCVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5NlkyLz5{M{S4PVI6OTxxYU6=
NFF	MnnBR5l1d3SxeHnjbZR6KGG\|c3H5		NWG0NVl[PzJiaILz		M2rEc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5HTiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDBwMEG2PUDPxE1w	M4TuSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5NlkyLz5{M{S4PVI6OTxxYU6=
NFF	MmXyR5l1d3SxeHnjbZR6KGG\|c3H5		NXW0PHlRPzJiaILz		MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNVch\|ryPLh?=	MoLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{MUWzOFgoRjJ\|MkG1N\|Q5RC:jPh?=
A549	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		MVy3NkBpenN?		NXHRfmlYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjB{IN88UU4>	MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{MUWzOFgoRjJ\|MkG1N\|Q5RC:jPh?=
KB	M4nyUmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVS3NkBpenN?		NVfPd3I1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODJizszNMi=>	NGjHR4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWyNlk2Oyd-Mk[1NlI6PTN:L3G+
PC3	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NV75XJg4PDhiaILz		NFLEb49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNlc3KM7:TT6=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEOyN{c,OjhyM{izNlM9N2F-
HEK	NYjZR\|hyS3m2b4TvfIlkcXS7IHHzd4F6		M1H0flczKGi{cx?=		MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISWsh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wN\|Eh\|ryPLh?=	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{MUWzOFgoRjJ\|MkG1N\|Q5RC:jPh?=
HeLa	MnnlR5l1d3SxeHnjbZR6KGG\|c3H5		NGGzPJQ4OiCqcoO=		MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yM{W4JO69VS5?	MnLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEmyPVEoRjJ\|NEi5NlkyRC:jPh?=
HeLa	NV71[5ZxS3m2b4TvfIlkcXS7IHHzd4F6		NYKyWW5ZPzJiaILz		MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFM3KM7:TT6=	M2nENlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1N\|Q5Lz5{M{KxOVM1QDxxYU6=
BT549	NGfGZVJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkntOFghcHK\|		NFnaWZpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA2PDd{IN88UU4>	M1rEUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
DU145	NEPlRXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFLSUFg1QCCqcoO=		MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC3NlMh\|ryPLh?=	NYiyXXdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g{OjNpPkK4NFM5OzJ\|PD;hQi=>
Leukemia cells	MV\BcpRqfHWvb4KgZZN{[Xl?		NH[2V4w1QCCqcoO=		M3;ySmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzleYtmdWmjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUCgQUAxNjFizszNMi=>	NH\adlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Leukemia cells	Moi5RY51cXS3bX;yJIF{e2G7		M4jHUFQ5KGi{cx?=		MmPoRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlEh\|ryPLh?=	MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Colon cancer cells	NUXBPZJvS3m2b4TvfIlkcXS7IHHzd4F6				MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOsJGdKPTBiPTCwMlEh\|ryPLh?=	NUPLdllCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
Leukemia cells	MmDtR5l1d3SxeHnjbZR6KGG\|c3H5				NUPHfFVMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOsJGdKPTBiPTCwMlEh\|ryPLh?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
Colon cancer cells	NWm0fGM2SW62aYT1cY9zKGG\|c3H5		M2\lOlQ5KGi{cx?=		NIfsN5ZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNUDPxE1w	M3HpblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Colon cancer cells	M4XkUWFvfGm2dX3vdkBie3OjeR?=		M1fJdVQ5KGi{cx?=		MV3BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFb3zvckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1mgQUAxNjFizszNMi=>	NITvRYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Leukemia cells	NY\sXHlqSW62aYT1cY9zKGG\|c3H5				NYfER\|VYSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdGW3a3XtbYEh[2WubIOsJGdKPTBiPTCwMlEh\|ryPLh?=	NH3Qcnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
Colon cancer cells	NW\lOGhFSW62aYT1cY9zKGG\|c3H5				M3\1TmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JINwdG:wIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4yKM7:TT6=	NUHnVYJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Leukemia cells	Ml;XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3\BWVQ5KGi{cx?=		MofqS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gcIV2c2WvaXGgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yKM7:TT6=	NVO4UVV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
Colon cancer cells	MnOwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmDjOFghcHK\|		M36wSGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkGg{txONg>?	NEjHUGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
Leukemia cells	M4PxSGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1frTlQ5KGi{cx?=		M4TmOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOSEQvF2u	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
Colon cancer cells	MmrtR5l1d3SxeHnjbZR6KGG\|c3H5		Mn:yOFghcHK\|		MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zIN88UU4>	NEC5dW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
Leukemia cells	Mnz6R5l1d3SxeHnjbZR6KGG\|c3H5		NWrycYpoPDhiaILz		M2rQeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOSEQvF2u	M4KyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
Colon cancer cells	M2C0S2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3\nXFQ5KGi{cx?=		NGH5XnBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV0yRTjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlEh\|ryPLh?=	MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
MDA-MB-231	NHW3NJdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVHUbIhXPDhiaILz		MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTF4NjFOwG0v	NX72N\|dFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g{OjNpPkK4NFM5OzJ\|PD;hQi=>
central nervous system cancer cells	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=				MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDj[Y51emGuIH7ldpZwfXNic4nzeIVuKGOjbnPldkBk\WyuczygS2k2OCB;IECuNVI2QDlizszNMi=>	NVWweXhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
prostate cancer cells	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=				MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMtKEeLNUCgQUAxNjF{NUi5JO69VS5?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
CNS	NEnpT2pCdnSrdIXtc5Ih[XO\|YYm=		NX3Jc3JQPDhiaILz		MoD6RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ17TJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOC5zMkW4PUDPxE1w	NXjQXnBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	MoXQRY51cXS3bX;yJIF{e2G7		NYnuVo11PDhiaILz		NEnEdGhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOTJ3OEmg{txONg>?	M4XhV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
CNS	NEHjXGNCdnSrdIXtc5Ih[XO\|YYm=				M{LtSGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNPWyC2dX3vdkBk\WyuczygS2k2OCB;IECuNVI2QDlizszNMi=>	NHHRWI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
prostate cancer cells	MYjBcpRqfHWvb4KgZZN{[Xl?				MlrCRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdJJwe3SjdHWgeJVud3JiY3XscJMtKEeLNUCgQUAxNjF{NUi5JO69VS5?	M3;PZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
CNS	NXG5UnV3SW62aYT1cY9zKGG\|c3H5		M320c\|Q5KGi{cx?=		MVHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFTmOgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLIE2gNE4yOyEQvF2u	NXrrfmZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	M{HKNWFvfGm2dX3vdkBie3OjeR?=		NUXLPJp3PDhiaILz		Ml\hRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icILvd5RifGViY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKKD1iMD6xN{DPxE1w	M4HLfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
prostate cancer cells	MlrES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWq0PEBpenN?		NVXVNnpFT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTNizszNMi=>	MlTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
CNS	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M37qU\|Q5KGi{cx?=		MVTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTNizszNMi=>	NVHqcYQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
CNS	NHTPcXlEgXSxdH;4bYNqfHliYYPzZZk>		NXTvZXlRPDhiaILz		MlzlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjF\|IN88UU4>	Ml:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
prostate cancer cells	NXnpOIJSS3m2b4TvfIlkcXS7IHHzd4F6		MkfpOFghcHK\|		NVzlOnVuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTNizszNMi=>	NHTFXms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
prostate cancer cells	NGGxN3hEgXSxdH;4bYNqfHliYYPzZZk>		MV60PEBpenN?		NH;jRm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxem:\|dHH0[UBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yOyEQvF2u	NFi4S\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
CNS	M1\ufWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIn2fnA1QCCqcoO=		M1TZ[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zMzFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Melanoma cells	M37FcWFvfGm2dX3vdkBie3OjeR?=		MoPpOFghcHK\|		NGLUbnZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDN[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOC5zNUi0PUDPxE1w	MmLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Melanoma cells	NFrjN2VEgXSxdH;4bYNqfHliYYPzZZk>				NXnxeG9qS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdWWuYX7vcYEh[2WubIOsJGdKPTBiPTCwMlE2QDR7IN88UU4>	M1zOVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Melanoma cells	Mn\TRY51cXS3bX;yJIF{e2G7				NXT5XHdYSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdWWuYX7vcYEh[2WubIOsJGdKPTBiPTCwMlE2QDR7IN88UU4>	MnXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
Melanoma cells	NFexUIpCdnSrdIXtc5Ih[XO\|YYm=		NVzpOWxlPDhiaILz		MoT6RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXXsZY5wdWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlE3KM7:TT6=	NF70OXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Melanoma cells	MmTNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NVPC[HhPT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zNjFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
Melanoma cells	MnXnR5l1d3SxeHnjbZR6KGG\|c3H5		MoHsOFghcHK\|		M3PmUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTZizszNMi=>	NUjvUolZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Melanoma cells	M3P5VGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkTwOFghcHK\|		NVn1eWRlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zNjFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
A549	NYnJNHB7SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYDK[4syPDhiaILz		M4fycmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xO\|E2KM7:TT6=	M3\FWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
NSCLC	NYewfoMzSW62aYT1cY9zKGG\|c3H5		MYS0PEBpenN?		NG\sZnZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUSB;IECuNlUh\|ryPLh?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
NSCLC	M{Hh[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV7qV2NtPDhiaILz		M{PaR2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNlUh\|ryPLh?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
NSCLC	M1\aVWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1rGTlQ5KGi{cx?=		MkjKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6yOUDPxE1w	M1\IfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
NSCLC	NFzFTVVEgXSxdH;4bYNqfHliYYPzZZk>		NEDGfWg1QCCqcoO=		NYX6dXFPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVlOFTFOgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4zPSEQvF2u	Mni2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
NSCLC	M4LyXGFvfGm2dX3vdkBie3OjeR?=				MoG2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgUnNEVENiY3XscJMtKEeLNUCgQUAxNjJ3MUG5JO69VS5?	MkjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
NSCLC	NVS4c45ESW62aYT1cY9zKGG\|c3H5		M1[xWFQ5KGi{cx?=		NHvycXVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4zPTFzOTFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Non-small cell lung carcinoma cells	M33kNGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NXj1e2VjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVm:wLYPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscJMtKEeLNUCgQUAxNjJ3MUG5JO69VS5?	NX7me\|ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
ovarian cancer cells	NHyxeodEgXSxdH;4bYNqfHliYYPzZZk>				M3\GN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
renal cancer cells	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=				NYrvXlZTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hemWwYXygZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	NXPGO\|RmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
breast cancer cells	M2XZcmN6fG:2b4jpZ4l1gSCjc4PhfS=>				MnnIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{whT0l3MDC9JFAvOzF4MkOg{txONg>?	NEn5d489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
ovarian cancer cells	NUPweFV1SW62aYT1cY9zKGG\|c3H5		NX7kVmhiPDhiaILz		M2\DRWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	M1y1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
renal cancer cells	NGL2OplCdnSrdIXtc5Ih[XO\|YYm=		NEDaTlM1QCCqcoO=		NIn3eFhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuN\|E3OjNizszNMi=>	NXjn[VlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
breast cancer cells	NV7aPVEzSW62aYT1cY9zKGG\|c3H5		MYW0PEBpenN?		MlP4RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQoLlZZN1KGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6zNVYzOyEQvF2u	NUT0U29ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
renal cancer cells	MoS0RY51cXS3bX;yJIF{e2G7				MofFRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdoVv[WxidIXtc5Ih[2WubIOsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
ovarian cancer cells	MYfBcpRqfHWvb4KgZZN{[Xl?				NIflT25CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBwfmG{aXHuJJR2dW:{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	M4fHSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
breast cancer cells	MVrBcpRqfHWvb4KgZZN{[Xl?				NELqdoxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBjemWjc4SgeJVud3JiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	NYfWcI5IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian cancer cells	MUnBcpRqfHWvb4KgZZN{[Xl?		NYD3TZhrPDhiaILz		NFLONItCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUSB;IECuN\|Ih\|ryPLh?=	M1HYNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
renal cancer cells	MXXBcpRqfHWvb4KgZZN{[Xl?		NXTUXI1UPDhiaILz		MlnnRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icnXuZYwh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJJF0hOC5\|MjFOwG0v	NXPUeJJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
breast cancer cells	MmrGRY51cXS3bX;yJIF{e2G7		MlzPOFghcHK\|		MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEcnXhd5Qh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJJF0hOC5\|MjFOwG0v	MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	Mlz2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFP1e2U1QCCqcoO=		MnXWS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
breast cancer cells	M1vrNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkLoOFghcHK\|		NIWxcIpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	NGPKTJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
ovarian cancer cells	M2fnR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUK2RoRQPDhiaILz		M1nISGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG93[XKrYX6gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	NXnBRZZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
breast cancer cells	NIeydJJEgXSxdH;4bYNqfHliYYPzZZk>		NX:0b3JDPDhiaILz		NFH1PY9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
renal cancer cells	MnHBR5l1d3SxeHnjbZR6KGG\|c3H5		M1nMTFQ5KGi{cx?=		MnrFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
ovarian cancer cells	NYTDRVBqS3m2b4TvfIlkcXS7IHHzd4F6		MUS0PEBpenN?		NXOxOlNGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4{OiEQvF2u	NXm2fFE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
renal cancer cells	Mk\rR5l1d3SxeHnjbZR6KGG\|c3H5		NHnKcIY1QCCqcoO=		M1TQXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	M2PSSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
ovarian cancer cells	M3y3c2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3\kZlQ5KGi{cx?=		MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
breast cancer cells	NUXkNYJSS3m2b4TvfIlkcXS7IHHzd4F6		Mk[5OFghcHK\|		NHjBRoFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	NXPRfGxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
Lu1	NG\GdoxEgXSxdH;4bYNqfHliYYPzZZk>		NX:5WXZXPzJiaILz		NVvFVI1yS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVHVzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjR6IN88UU4>	M13MR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVU{Lz5{NkWyNlk2OzxxYU6=
MCF7	MkHuR5l1d3SxeHnjbZR6KGG\|c3H5		MVy3NkBpenN?		NWPtVpZuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC53MTFOwG0v	M{jtblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVU{Lz5{NkWyNlk2OzxxYU6=
HepG2	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		NEn0N4I4OiCqcoO=		MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE43QSEQvF2u	NEHQRm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWyNlk2Oyd-Mk[1NlI6PTN:L3G+
COLON	NF;XXnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWq0PEBpenN?		NWDob4JrT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMz65PEDPxE1w	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
COLON	MkPXR5l1d3SxeHnjbZR6KGG\|c3H5		MYi0PEBpenN?		MlzRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOy57ODFOwG0v	NUPHW4h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
COLON	NWXudWhuS3m2b4TvfIlkcXS7IHHzd4F6		M4nQflQ5KGi{cx?=		NVT0[2FqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0:OT16gZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCzMlk5KM7:TT6=	M1XLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
COLON	NHnXZoZEgXSxdH;4bYNqfHliYYPzZZk>				Mln3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzMEBVT0liPTCzMlk5OTB5IN88UU4>	NYLud4M6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
COLON	MlK2RY51cXS3bX;yJIF{e2G7		M4rIS\|Q5KGi{cx?=		M{jUWGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPvcI9vKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDUS2khRSB\|Lkm4NVA4KM7:TT6=	MoPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
COLON	M1Hxc2FvfGm2dX3vdkBie3OjeR?=				MmOwRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgZ49td25idIXtc5Ih[2WubIOsJHRIUSB;IEOuPVgyODdizszNMi=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
central nervous system cancer cells	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=				NWLkO4pKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2WwdILhcEBv\XK4b4XzJJN6e3SnbTDjZY5k\XJiY3XscJMtKFSJSTC9JFYvOzB7NUeg{txONg>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
prostate cancer cells	NIezSmhEgXSxdH;4bYNqfHliYYPzZZk>				MlP2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{NCCWR1mgQUA3NjNyOUW3JO69VS5?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
CNS	MXTBcpRqfHWvb4KgZZN{[Xl?		NH7jUIM1QCCqcoO=		MXzBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFTmOgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKFSJSTC9JFYvOzB7NUeg{txONg>?	NHj2R5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
prostate cancer cells	NHvjbm5CdnSrdIXtc5Ih[XO\|YYm=		NHP0WIs1QCCqcoO=		M1HOPGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC2MlMxQTV5IN88UU4>	NUm4TodJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
CNS	MVvBcpRqfHWvb4KgZZN{[Xl?				MWnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDDUnMhfHWvb4KgZ4VtdHNuIGTHTUA:KDZwM{C5OVch\|ryPLh?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
prostate cancer cells	NYLGUmp6SW62aYT1cY9zKGG\|c3H5				MXHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDwdo9{fGG2ZTD0eY1weiClZXzsd{whXEeLIE2gOk4{ODl3NzFOwG0v	NEHwfGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
prostate cancer cells	M1njV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NULvcYNMPDhiaILz		M1zBNGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJJBzd3O2YYTlJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IE[uN\|Eh\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
CNS	NXjDeGdIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX:0PEBpenN?		NXG5R4RDT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDZwM{Gg{txONg>?	MnKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
CNS	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		NIjm[oI1QCCqcoO=		NVW0T5d7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDZwM{Gg{txONg>?	NH;LOWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
prostate cancer cells	NIjYPXFEgXSxdH;4bYNqfHliYYPzZZk>		NF3xc4I1QCCqcoO=		Mm\rR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNj6zNUDPxE1w	Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
prostate cancer cells	NU\v[nhkS3m2b4TvfIlkcXS7IHHzd4F6		MYS0PEBpenN?		MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB4LkOxJO69VS5?	NYXteZo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
CNS	NYGyUpZNS3m2b4TvfIlkcXS7IHHzd4F6		M37qXVQ5KGi{cx?=		NGjobnREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEVlNiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hPi5\|MTFOwG0v	NInBcoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
Melanoma cells	MmrKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYK0PEBpenN?		MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDt[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	MmnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
breast cancer cells	M1TUR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUW0PEBpenN?		MnHuS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDdwOUSg{txONg>?	M1r0O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
breast cancer cells	M1;pdmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXvQdHZ1PDhiaILz		MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hPy57NDFOwG0v	NEW4U409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
Melanoma cells	MnnSR5l1d3SxeHnjbZR6KGG\|c3H5		MYe0PEBpenN?		MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDt[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	NWnnXFk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Melanoma cells	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=		MXu0PEBpenN?		M2G3fGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gO{46PCEQvF2u	NG[wbJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
breast cancer cells	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		M2DPOFQ5KGi{cx?=		M4r3d2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB5Lkm0JO69VS5?	NHXpUpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
Melanoma cells	Mk\FRY51cXS3bX;yJIF{e2G7		NF7jWZc1QCCqcoO=		MVXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPZXzhco9u[SClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC3Mlk1OzJ6IN88UU4>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Melanoma cells	NH[3epFEgXSxdH;4bYNqfHliYYPzZZk>				MoPFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcYVt[W6xbXGgZ4VtdHNuIGTHTUA:KDdwOUSzNlgh\|ryPLh?=	M3XTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
breast cancer cells	NEnMVFREgXSxdH;4bYNqfHliYYPzZZk>				MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHzzMEBVT0liPTC3Mlk1OzJ6IN88UU4>	NGTJbHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
breast cancer cells	M3vhTGFvfGm2dX3vdkBie3OjeR?=		NUjDUIZJPDhiaILz		NW\nTW9vSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC3Mlk1OzJ6IN88UU4>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Melanoma cells	NV21U28xSW62aYT1cY9zKGG\|c3H5				NGTFd41CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBu\Wyjbn;tZUBk\WyuczygWGdKKD1iNz65OFMzQCEQvF2u	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
breast tumor cells	MU\BcpRqfHWvb4KgZZN{[Xl?				MUfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDidoVie3RidIXtc5Ih[2WubIOsJHRIUSB;IEeuPVQ{OjhizszNMi=>	M4DXelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
NSCLC	NILSVmFCdnSrdIXtc5Ih[XO\|YYm=				MnXFRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgUnNEVENiY3XscJMtKFSJSTC9JFE2Njh2OEmg{txONg>?	NYTtNpJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Leukemia cells	NXLPfYM3SW62aYT1cY9zKGG\|c3H5		M1\Ne\|Q5KGi{cx?=		NFX4SnhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDM[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCWR1mgQUAyPS56NEi5JO69VS5?	NFixNpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
NSCLC	MWDBcpRqfHWvb4KgZZN{[Xl?		NVnRb5UxPDhiaILz		NGPBNnJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTCxOU45PDh7IN88UU4>	M3zIS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Non-small cell lung carcinoma cells	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=				NXrEOGFMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVm:wLYPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscJMtKFSJSTC9JFE2Njh2OEmg{txONg>?	NGjBVII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
Leukemia cells	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=				MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDs[ZVs\W2rYTDj[YxteyxiVFfJJF0hOTVwOES4PUDPxE1w	M3;6R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Leukemia cells	MkexRY51cXS3bX;yJIF{e2G7				NHy1eYtCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBt\XWtZX3pZUBk\WyuczygWGdKKD1iMUWuPFQ5QSEQvF2u	NWXQ[pdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
NSCLC	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGXMemU1QCCqcoO=		MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF3Lki1JO69VS5?	NV3LUmg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
Leukemia cells	NHryTIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmnsOFghcHK\|		NX3DSIgxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyPS56NTFOwG0v	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
NSCLC	NEn1[5dEgXSxdH;4bYNqfHliYYPzZZk>		MUS0PEBpenN?		M1v5b2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUWuPFUh\|ryPLh?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Leukemia cells	M4fLcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWC0PEBpenN?		MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDs[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG1Mlg2KM7:TT6=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
NSCLC	NFnySVlEgXSxdH;4bYNqfHliYYPzZZk>		MknwOFghcHK\|		MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF3Lki1JO69VS5?	NI[4UYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
Leukemia cells	MnTiR5l1d3SxeHnjbZR6KGG\|c3H5		MlfXOFghcHK\|		MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDs[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG1Mlg2KM7:TT6=	NGW0c\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
renal cancer cells	NWGwOml7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUG0PEBpenN?		NILSVoNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzOT65OUDPxE1w	NX3yfZR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
ovarian cancer cells	NHr2RoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWe0PEBpenN?		NWC4TI9iT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCxPU46PSEQvF2u	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
renal cancer cells	M3LVe2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M{\nclQ5KGi{cx?=		Mm\JR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOTlwOUWg{txONg>?	NEDSV4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
ovarian cancer cells	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=		MmTVOFghcHK\|		MmDQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzOT65OUDPxE1w	M{\FUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
renal cancer cells	NXHO[283S3m2b4TvfIlkcXS7IHHzd4F6		MUK0PEBpenN?		Mn3BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOTlwOUWg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
ovarian cancer cells	NXHYTo9pS3m2b4TvfIlkcXS7IHHzd4F6		NWe5U2o2PDhiaILz		MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF7Lkm1JO69VS5?	NETIW2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
ovarian cancer cells	NYLn[lZQS3m2b4TvfIlkcXS7IHHzd4F6				M1:2ZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIx{NCCWR1mgQUAyQS57NUK2JO69VS5?	M3\NNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
renal cancer cells	MVjDfZRwfG:6aXPpeJkh[XO\|YYm=				MnHjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzMEBVT0liPTCxPU46PTJ4IN88UU4>	MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
ovarian cancer cells	NIHER5JCdnSrdIXtc5Ih[XO\|YYm=		MoLrOFghcHK\|		MknmRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygWGdKKD1iMUmuPVUzPiEQvF2u	NIHYO5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	M3jNcmFvfGm2dX3vdkBie3OjeR?=		MoixOFghcHK\|		MUjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiC{ZX7hcEBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiVFfJJF0hOTlwOUWyOkDPxE1w	Mkj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal tumor cells	MWDBcpRqfHWvb4KgZZN{[Xl?				MkLXRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdoVv[WxidIXtc5Ih[2WubIOsJHRIUSB;IEG5Mlk2OjZizszNMi=>	NUjGVWxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian tumor cells	NH3XcI5CdnSrdIXtc5Ih[XO\|YYm=				MoPxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4Sgc5ZiemmjbjD0eY1weiClZXzsd{whXEeLIE2gNVkvQTV{NjFOwG0v	M1rKSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
PC3	MoXmR5l1d3SxeHnjbZR6KGG\|c3H5		MYS0PEBpenN?		M2XKeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{OD6xNUDPxE1w	MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NVYoRjJ7MUe0PFE3RC:jPh?=
neural precursor cells	NYDjZ\|Z7TnWwY4Tpc44h[XO\|YYm=				M1yxVWlvcGmkaYTpc44hd2ZibnX1do9{eGincnWgdJJwdGmoZYLheIlwdiCxZjDtc5V{\SCwZYXyZYwheHKnY4Xyd49zKGOnbHzzJIJ6KE2WVDDhd5NigQ>?	NIXGRnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxO\|Y{OSd-MUe0NVc3OzF:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

体内研究

Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠，平均生长延迟120天和52天以上，且再植指数分别为0.06％和5％。^[5] Vincristine 处理小鼠，通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量，降低近75%。^[6]

细胞实验：^[1]	- 合并 Cell lines: B16 黑色素瘤细胞 Concentrations: 10 nM Incubation Time: 3 天 Method: 细胞按5 × 10⁴ cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上，在37°C下含5% CO₂ 和95% 空气的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基，继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后，每天使用库氏计数器完成细胞计数 (Only for Reference)
动物实验：^[5]	- 合并 Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠 Dosages: 3 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： Saline	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vincristine (NSC-67574) sulfate SDF

分子量	923.04
化学式	C₄₆H₅₈N₄O₁₄S
CAS号	2068-78-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Leurocristine, Oncovin, 22-Oxovincaleukoblastine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04448834	Suspended	Drug: Blinatumomab	B-cell Acute Lymphoblastic Leukemia	Dorothy Sipkins MD PhD\|Amgen\|Acrotech Biopharma LLC\|Duke University	May 24 2021	Phase 2
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 13 2019	Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
回答：
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

研究领域

产品类型

定制您的化合物库

Vincristine (NSC-67574) sulfate

客户使用Selleck生产的Vincristine (NSC-67574) sulfate发表文献97篇：

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vincristine (NSC-67574) sulfate SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

常见问题及建议解决方法